BCM
ATXI

Bayesian Capital Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Bayesian Capital Management’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-147
Closed -$12.8K – 1148
2022
Q4 		$12.8K Buy
+147
New +$26.7K ﹤0.01% 731

Other funds holding ATXI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
IWP
Icon Wealth Partners Houston, Texas $880M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bayesian Capital Management's ATXI Position: Q1 2023 in Review

Bayesian Capital Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2023, closing a stake of 147 shares — an estimated $12.8K sold.

Bayesian Capital Management first reported a position in ATXI in Q4 2022 and held it in 1 quarter. The position peaked at $12.8K in Q4 2022. 13 funds tracked by Wall St. Rank hold ATXI as of Q1 2023.

  • Bayesian Capital Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Bayesian Capital Management sold 147 Avenue Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $12.8K.
  • Bayesian Capital Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Bayesian Capital Management's Avenue Therapeutics, Inc. Common Stock position peaked at $12.8K in Q4 2022.
  • 13 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Bayesian Capital Management's 13F filing for Q1 2023, filed 15 May 2023.